A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: Pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand

Pediatric Infectious Disease Journal

Volumn 29, Issue 10, 2010, Pages 940-944

  Vanprapar, Nirun ^a   Cressey, Tim R ^b,c   Chokephaibulkit, Kulkanya ^a   Muresan, Petronella ^c   Plipat, Nottasorn ^d   Sirisanthana, Virat ^b   Prasitsuebsai, Wasana ^a   Hongsiriwan, Suchat ^e   Chotpitayasunondh, Tawee ^f   Eksaengsri, Achara ^g   Toye, Maripat ^h   Smith, Mary Elizabeth ⁱ   McIntosh, Kenneth ^j   Capparelli, Edmund ^k   Yogev, Ram ^l  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e CHONBURI HOSPITAL   (Thailand)

^f QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

^g Thailand Government Pharmaceutical Organization   (Thailand)

^h BAYSTATE MEDICAL CENTER   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j BOSTON CHILDREN S HOSPITAL   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l CHILDREN'S MEMORIAL HOSPITAL   (United States)

more..

Author keywords

antiretrovirals; children; fixed dose combinations; pharmacokinetics; Thailand

Indexed keywords

LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; STAVUDINE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHEWABLE TABLET; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FEVER; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; NEUTROPHIL COUNT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 77957278518     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181e2189d     Document Type: Article

References (31)

1. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis. 2005;41:100-107. (Pubitemid 40863751)
2. Lapphra K, Vanprapar N, Chearskul S, et al. Efficacy and tolerability of nevirapine-versus efavirenz-containing regimens in HIV-infected Thai children. Int J Infect Dis. 2008;12:e33-e38.
3. O'Brien DP, Sauvageot D, Zachariah R, et al. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS. 2006;20:1955-1960. (Pubitemid 44427613)
4. Chokephaibulkit K, Plipat N, Cressey TR, et al. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS. 2005;19:1495-1499. (Pubitemid 41400695)
5. Puthanakit T, Aurpibul L, Sirisanthana T, et al. Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less. Pediatr Infect Dis J. 2009;28:246-248.
6. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr Infect Dis J. 2007;26:953-956. (Pubitemid 47494171)
7. WHO Library Cataloguing-in-Publication Data. Preferred antiretroviral medicines for treating and preventing HIV infection in younger children: Report of the WHO Paediatric Antiretroviral Working Group, ISBN 978 92 4 159661 9. World Health Organization; 2008.
8. Thailand. Department of Disease Control. Textbook of Thailand National Antiretroviral Treatment Guideline 2006/2007. Bangkok: The Agricultural Co-operative Federation of Thailand; 2009.
9. Kaul S, Kline MW, Church JA, et al. Determination of dosing guidelines for stavudine (2,3-didehydro-3-deoxythymidine) in children with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2001;45: 758-763. (Pubitemid 32182021)
10. Johnson MA, Moore KH, Yuen GJ, et al. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36:41-66.
11. Viramune package insert. Ridgefield, CT: Boehringer Ingelheim Corp; 2005.
12. Capparelli E, Blanchard S, Aweeka F, et al. Population pharmacokinetics of nevirapine in infants and children-the impact of body size, age, and concomitant therapies (Abstract 37). In: 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28-30, 2005; Quebec, Canada.
13. Acosta EP, Gerber JG; Adult Pharmacology Committee of the AIDS Clinical Trials Group. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses. 2002;18:825-834. (Pubitemid 35034663)
14. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit. 2003;25:393-399.
15. Holland DT, DiFrancesco R, Connor JD, et al. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther Drug Monit. 2006;28: 367-374.
16. Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS. 2001;15:1089-1095.
17. Stavudine (Zerit) package insert. Princeton, NJ: Bristol-Myers Squibb; 2006.
18. Report from Thai Government Pharmaceutical Organization (Study 786/06): GPO-VIR S30 study in Thai adult, 2006.
19. Bruno R, Regazzi MB, Ciappina V, et al. Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV. Clin Pharmacokinet. 2001;40:695-700. (Pubitemid 32954991)
20. Hosseinipour MC, Corbett AH, Kanyama C, et al. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults. AIDS. 2007;21:59-64. (Pubitemid 44912537)
21. Vezina HE, Henry K, Ravindran GD, et al. A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India. J Acquir Immune Defic Syndr. 2006;41:131-136.
22. L'Homme RF, Kabamba D, Ewings FM, et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS. 2008;22:557-565. (Pubitemid 351640588)
23. Burger DM, Verweel G, Rakhmanina N, et al. Age-dependent pharmacokinetics of lamivudine in HIV-infected children. Clin Pharmacol Ther. 2007;81:517-520. (Pubitemid 46452314)
24. de Vries-Sluijs TE, Dieleman JP, Arts D, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet. 2003;42:599-605. (Pubitemid 36805618)
25. Duong M, Buisson M, Peytavin G, et al. Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors. Ann Pharmacother. 2005;39:603-609. (Pubitemid 40396611)
26. Verweel G, Sharland M, Lyall H, et al. Nevirapine use in HIV-1-infected children. AIDS. 2003;17:1639-1647. (Pubitemid 36951685)
27. Mulenga V, Fillekes Q, Kabamba D, et al. Pharmacokinetics of nevirapine in 3-to 6-kg, HIV-infected infants taking pediatric fixed-dose combination tablets. In: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada. Abstract 881.
28. Mosha LB, Musoke P, Parsons T, et al. Nevirapine concentrations in HIV-infected Ugandan children on adult fixed-dose combination tablet ART, with and without rifampicin-based treatment for active M. tuberculosis infection. In: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada. Abstract 909.
29. Luzuriaga K, Bryson Y, McSherry G, et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis. 1996;174:713-721. (Pubitemid 26325885)
30. Browne MJ, Mayer KH, Chafee SB, et al. 2,3-didehydro-3-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis. 1993;167:21-29. (Pubitemid 23002832)
31. Taylor P, Worrell C, Steinberg SM, et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virusinfected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics. 2004;114:e235-e242.